Get the Stockscreener App
966.99
1.95%
18.54
After Hours:
966.00
-0.99
-0.10%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $966.99, with a volume of 3.11M.
It is up +1.95% in the last 24 hours and up +2.93% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$948.45
Open:
$949
24h Volume:
3.11M
Relative Volume:
0.98
Market Cap:
$862.31B
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
34.81
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
-0.10%
1M Performance:
+2.93%
6M Performance:
-2.19%
1Y Performance:
+31.64%
1-Day Range:
$943.26
$995.00
1-Week Range:
$943.26
$996.49
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
966.99 | 845.77B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
221.43 | 532.77B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
202.78 | 356.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
181.86 | 283.57B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
145.23 | 278.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Barclays Sees Reinforced Long-Term Growth Narrative for Eli Lilly and Company (LLY) - Insider Monkey
What's Ailing the Biggest Healthcare ETF? Eli Lilly, GLP-1 Troubles Are a Start. -- Barrons.com - Moomoo
Exclusive: Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity - Reuters
Income or Growth: Which Healthcare Stock Fits Your Portfolio Right Now? - The Motley Fool
Exclusive-Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity - AOL.com
Eli Lilly and Co Stock (LLY) Moved Up by 4.36% on May 11: Drivers Behind the Movement - TradingKey
Eli Lilly CFO Lucas Montrace explains what drove 56% year-over-year revenue beat - qz.com
Why is Eli Lilly stock climbing today? - Investing.com
Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term - Yahoo Finance Singapore
Eli Lilly stock (US5324571083): Q1 revenue surge 56% on obesity drug boom - AD HOC NEWS
Pfizer vs Eli Lilly: Different Bets on Pharma M&A - 24/7 Wall St.
NYSE Content Update: Eli Lilly to Celebrate 150 Years of Scientific Innovation - PA Media
Eli Lilly & Co. stock (US5324571083): Q1 revenues surge 56% on obesity drug boom - AD HOC NEWS
Omada Health posts 42% revenue jump in Q1, joins Eli Lilly employer weight loss program - Fierce Healthcare
Eli Lilly & Co. (NYSE:LLY) Passes the "Little Book That Makes You Rich" Growth Screen - ChartMill
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,400 - Moomoo
Novo Nordisk loses China momentum: Analysts point out Eli Lilly's special advantage - medwatch.com
Eli Lilly's Mounjaro surpasses Merck's Keytruda as best-selling drug - MSN
Eli Lilly's Mounjaro Surpasses Merck's Keytruda as Best-Selling Drug - 조선일보
Eli Lilly: 'Strong Buy' Raised Revenue Guidance By $2 Billion For 2026 And Label Expansions - Seeking Alpha
Insider Frenzy at JPMorgan, Chevron, Eli Lilly, Berkshire, Strategy - TipRanks
Eli Lilly & Co. stock (US5324571083): Obesity and diabetes growth drive investor focus - AD HOC NEWS
Is This News From Novo Nordisk a Warning for Eli Lilly Shareholders? - AOL.com
LLY6388968 Bond Price and Chart — FINRA:LLY6388968 - TradingView
Jean Santana Appointed as Senior Director – Global People Strategy, Manufacturing & Quality at Eli Lilly and Company - hrtoday.in
LLY6388974 Bond Price and Chart — FINRA:LLY6388974 - TradingView
Eli Lilly Stock Hits Bottleneck After 400% Surge in Five Years, Novo Nordisk Poised for a Comeback with 4% Dividend Yield - NAI500
Stock Quote & Chart | Eli Lilly and Company - investor.lilly.com
Lilly's Next Obesity Drug Is So Powerful It's Already Getting Copied - Investor's Business Daily
GLP-1 battle heats up between Eli Lilly and Novo Nordisk - Yahoo Finance UK
Lilly to invest extra $4.5B across Indiana manufacturing - Manufacturing Dive
Parkland board hesitates on tax abatement for Eli Lilly - Lehigh Valley Press
Omada Health (OMDA) Q1 2026 Earnings Transcript - The Globe and Mail
Lilly's obesity pill tops 7,000 prescriptions in fourth week, signals modest uptake - Reuters
Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There. - Yahoo Finance
Eli Lilly and Company 8-K Filing May 2026 – SEC Document Details, Registered Securities & Company Information - Minichart
Lilly invests $4.5B in Indiana manufacturing, opens doors of 1st genetic medicine site - PharmaLive
Here is Why Eli Lilly (LLY) is One of the Best Stocks to Buy for the Next 15 Years - Insider Monkey
Eli Lilly (LLY) issues $9.0B multi‑tranche notes; Centessa redemption clause included - Stock Titan
Eli Lilly Stock a Strong Buy in 2026 as Mounjaro, Zepbound Demand Fuels Blowout Growth and Analyst Upside - International Business Times Australia
Eli Lilly's (NYSE:LLY) Earnings Are Weaker Than They Seem - Yahoo Finance
LLY Stock Price, Quote & Chart | ELI LILLY & CO (NYSE:LLY) - ChartMill
Major Legacy Investor Makes a Powerful Move in Eli Lilly Stock - TipRanks
Eli Lilly Shareholders Back Board, Maintain Governance Structure - TipRanks
Omada Health joins Eli Lilly employer weight loss program - Investing.com
Eli Lilly revives dollar market with $9bn M&A financing - GlobalCapital
Declaration of Voting Results by Eli Lilly - marketscreener.com
Eli Lilly (NYSE: LLY) investors back board, keep supermajority rules - Stock Titan
44% of surveyed GLP-1 patients pay over $250 a month as Omada adds Lilly channel - Stock Titan
Eli Lilly & Co. stock underperforms Thursday when compared to competitors - MarketWatch
Lilly Endowment Inc. sells Eli Lilly (NYSE:LLY) stock worth $15.75 million - Investing.com
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):